Long-term efficacy of tenofovir alafenamide in HBeAg-positive and -negative chronic hepatitis B patients treated for up to 8 years in 2 phase 3 studies

被引：0

作者：

Buti, Maria ^{[1
,2
]}

Agarwal, Kosh ^{[3
]}

Chan, Henry Ly ^{[4
]}

Seto, Wai-Kay ^{[5
,6
]}

Lim, Young-Suk ^{[7
]}

Brunetto, Maurizia ^{[8
]}

Chuang, Wan-Long ^{[9
]}

Janssen, Harry ^{[10
,11
]}

Fung, Scott ^{[12
]}

Izumi, Namiki ^{[13
]}

Jablkowski, Maciej ^{[14
]}

Abramov, Frida ^{[15
]}

Wang, Hongyuan ^{[15
]}

Yee, Leland ^{[15
]}

Mateo, Roberto ^{[15
]}

Flaherty, John F. ^{[15
]}

Pan, Calvin ^{[16
]}

Shalimar ^{[17
]}

Marcellin, Patrick ^{[18
]}

Gane, Edward J. ^{[19
]}

机构：

[1] Hosp Univ Vall dHebron, Barcelona, Spain

[2] CIBEREHD Inst Carlos III, Madrid, Spain

[3] Kings Coll Hosp NHS Fdn Trust, Inst Liver Studies, London, England

[4] Chinese Univ Hong Kong, 9F Union Hosp, HMA Off, Tai Wai, Hong Kong, Peoples R China

[5] Univ Hong Kong, Dept Med, Pok Fu Lam, Hong Kong, Peoples R China

[6] Univ Hong Kong, Sch Clin Med, Pok Fu Lam, Hong Kong, Peoples R China

[7] Univ Ulsan, Asan Med Ctr, Coll Med, Seoul, South Korea

[8] Azienda Osped Univ Pisana, Pisa, Italy

[9] Kaohsiung Med Univ Hosp, Kaohsiung, Taiwan

[10] Univ Hlth Network, Toronto Ctr Liver Dis, Toronto, ON, Canada

[11] Erasmus MC, Rotterdam, Netherlands

[12] Univ Toronto, Dept Med, Toronto, ON, Canada

[13] Japanese Red Cross Musashino Hosp, Dept Gastroenterol & Hepatol, Tokyo, Japan

[14] Med Univ Lodz, Lodz, Poland

[15] Gilead Sci Inc, Foster City, CA USA

[16] New York Univ, NYU Langone Hlth, Grossman Sch Med, New York, NY USA

[17] All India Inst Med Sci, New Delhi, India

[18] Hop Beaujon, Hepatol Dept, Clichy, France

[19] Auckland Clin Studies, Symonds St, Auckland, New Zealand

来源：

JOURNAL OF HEPATOLOGY | 2023年 / 78卷

关键词：

D O I：

暂无

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

OS-067

引用

页码：S57 / S57

页数：1

共 50 条

[1] LONG-TERM EFFICACY OF TENOFOVIR ALAFENAMIDE IN HBEAG-POSITIVE AND -NEGATIVE CHRONIC HEPATITIS B PATIENTS TREATED FOR UP TO 8 YEAR IN 2 PHASE 3 STUDIES
Buti, Maria
Agarwal, Kosh
Chan, Henry L.
Seto, Wai-Kay
Lim, Young-Suk
Brunetto, Maurizia R.
Chuang, Wan-Long
Janssen, Harry L.
Fung, Scott
Izumi, Namiki
Jablkowski, Maciej
Abramov, Frida
Wang, Hongyuan
Yee, Leland J.
Mateo, Roberto
Flaherty, John F.
Pan, Calvin Q.
Marcellin, Shalimar Patrick
Gane, Edward
GASTROENTEROLOGY, 2024, 166 (05) : S1604 - S1604
[2] Three Year Efficacy and Safety of Tenofovir Alafenamide (TAF) Compared to Tenofovir Disoproxil Fumarate (TDF) in Hbeag-Negative and Hbeag-Positive Patients with Chronic Hepatitis B
Chan, Henry Lik Yuen
Lim, Young-Suk
Seto, Wai Kay Walter
Agarwal, Kosh
Brunetto, Maurizia R.
Janssen, Harry L. A.
Caruntu, Florin
Stepanova, Tatjana
Tsang, Owen
Yatsuhashi, Hiroshi
Tak, Won Young
Chen, Chi-Yi
Celen, Mustafa
Suri, Vithika
Flaherty, John F.
Lin, Lanjia
Cathcart, Andrea
Gaggar, Anuj
Pan, Calvin Q.
Shalimar
Buti, Maria
HEPATOLOGY, 2018, 68 : 227A - 228A
[3] Long-term follow-up of HBeAg-positive patients treated with interferon alfa for chronic hepatitis B
Niederau, C
Heintges, T
Lange, S
Goldmann, G
Niederau, CM
Mohr, L
Haussinger, D
NEW ENGLAND JOURNAL OF MEDICINE, 1996, 334 (22): : 1422 - 1427
[4] Predictors of HBeAg loss in HBeAg-positive patients with chronic hepatitis B during treatment with tenofovir alafenamide or tenofovir disoproxil fumarate
Pan, Calvin Q.
Li, Michael Kin Kong
Lee, Kwan Sik
Balabanska, Rozalina I.
Flaherty, John F.
Kim, Kyungpil
Myers, Robert P.
Subramanian, Mani
Abdurakhmanov, Djamal
Ma, Mang M.
Bae, Ho
Agarwal, Kosh
HEPATOLOGY, 2016, 64 : 931A - 931A
[5] Predictors of HBeAg loss in HBeAg-positive patients with chronic hepatitis B during treatment with tenofovir alafenamide or tenofovir disoproxil fumarate
Flaherty, J.
Kim, K.
Jackson, A.
Myers, R.
Subramanian, M.
Agarwal, K.
Kong, M. Kin
Lee, K. S.
Balabanska, R.
Ma, M.
Pan, C.
Abdurakhmanov, D.
Bae, H.
HIV MEDICINE, 2017, 18 : 42 - 43
[6] Improved bone and renal safety of switching from tenofovir disoproxil fumarate to tenofovir alafenamide: preliminary results from 2 phase 3 studies in HBeAg-positive and HBeAg-negative patients with chronic hepatitis B
Chan, H. L.
Fung, S.
Seto, W. K.
Gane, E.
Flaherty, J. F.
Suri, V.
Lin, L.
Gaggar, A.
Subramanian, G. M.
Chuang, W. L.
Agarwal, K.
Janssen, H. L.
Buti, M.
JOURNAL OF HEPATOLOGY, 2017, 66 (01) : S25 - S25
[7] NO RESISTANCE TO TENOFOVIR ALAFENAMIDE ( TAF) IN ADULT, HBEAG- POSITIVE AND HBEAG- NEGATIVE PARTICIPANTS WITH CHRONIC HEPATITIS B INFECTION TREATED WITH TAF FOR UP TO 8 YEARS.
Mateo, Roberto
Chan, Henry Lik Yuen
Marcellin, Patrick
Pan, Calvin Pan
Yazdi, Tahmineh
Chang, Silvia
Han, Dong
May, Lindsey
Marceau, Caleb
Richards, Christopher
Manhas, Savrina
Ho, Pui Yan
Li, Robert
Xu, Simin
Martinez, Clarissa
Liu, Yang
Peinovich, Nadine
Lopez, Andrew
Abramov, Frida
Flaherty, John F.
Mo, Hongmei
Izumi, Namiki
Buti, Maria
Dr Shalimar
Lim, Young-Suk
HEPATOLOGY, 2023, 78 : S532 - S533
[8] Improved bone and renal safety of switching from tenofovir disoproxil fumarate to tenofovir alafenamide: Preliminary results from two phase 3 studies in HBeAg-positive and HBeAg-negative patients with chronic hepatitis B
Thompson, A.
Gane, E.
Fung, S.
Seto, W. K.
Flaherty, J. F.
Suri, V.
Lin, L.
Gaggar, A.
Subramanian, G. M.
Chuang, W. L.
Agarwal, K.
Janssen, H. L.
Buti, M.
Chan, H. L.
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2017, 32 : 109 - 109
[9] Long-term outcomes of pegylated interferon and tenofovir treatment for HBeAg-positive chronic hepatitis B infection
Roberts, A.
Ng, J.
Dev, A.
O'Neill, P.
Sievert, W.
Bell, S.
Ratnam, D.
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2021, 36 : 81 - 81
[10] HBeAg levels at week 24 predict response to 8years of tenofovir in HBeAg-positive chronic hepatitis B patients
Wong, D.
Littlejohn, M.
Yuen, L.
Jackson, K.
Mason, H.
Bayliss, J.
Rosenberg, G.
Gaggar, A.
Kitrinos, K.
Subramanian, M.
Marcellin, P.
Buti, M.
Janssen, H. L. A.
Gane, E.
Locarnini, S.
Thompson, A.
Revill, P. A.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2018, 47 (01) : 114 - 122

← 1 2 3 4 5 →